Pernow J, Saria A, Lundberg J M
Acta Physiol Scand. 1986 Feb;126(2):239-49. doi: 10.1111/j.1748-1716.1986.tb07811.x.
The effects of porcine neuropeptide Y (NPY) regarding sympathetic vascular control were studied in vitro on isolated rat blood vessels. The 10(-9)M NPY enhanced (about two-fold) the contractile responses to transmural nerve stimulation (TNS), noradrenaline (NA) and adrenaline (about two-fold) in the femoral artery. Higher concentrations of NPY (greater than 10(-8)M) caused an adrenoceptor-resistant contraction per se. The TNS-evoked [3H]NA efflux was significantly reduced by NPY in a concentration-dependent manner (threshold 10(-9)M). The calcium antagonist, nifedipine, abolished the contractile effects of NPY and the NPY-induced enhancement of NA contractions but did not influence the prejunctional inhibition of [3H]NA release. Receptor-binding studies showed that the ratio of alpha 1-to alpha 2-adrenoceptors in the femoral artery was 30:1. The NPY did not cause any detectable change in the number of alpha 1-or alpha 2-adrenoceptor binding sites or in the affinity of alpha 2-binding sites, as revealed by prazosin- and clonidine-binding, respectively. The NPY also inhibited the TNS-evoked [3H]NA release (by 42-86%) in the superior mesenteric and basilar arteries and in femoral and portal veins. The NPY still depressed TNS-evoked [3H]NA secretion from the portal vein in the presence of phentolamine. The NPY caused a clear-cut contraction in the basilar artery, increased the contractile force of spontaneous contractions in the portal vein, while only weak responses were observed in the superior mesenteric artery and femoral vein. The NA-induced contraction was markedly enhanced by NPY in the superior mesenteric artery, only slightly enhanced in the portal vein and uninfluenced in the femoral vein. In conclusion, in all blood vessels tested, NPY depresses the TNS-evoked [3H]NA secretion via a nifedipine-resistant action. Furthermore, NPY exerts a variable, Ca2+-dependent vasoconstrictor effect and enhancement of NA and TNS contractions.
在体外对分离的大鼠血管研究了猪神经肽Y(NPY)对交感神经血管控制的影响。10⁻⁹M的NPY增强了(约两倍)股动脉对跨壁神经刺激(TNS)、去甲肾上腺素(NA)和肾上腺素(约两倍)的收缩反应。更高浓度的NPY(大于10⁻⁸M)本身会引起一种抗肾上腺素能受体的收缩。NPY以浓度依赖性方式显著降低TNS诱发的[³H]NA流出(阈值为10⁻⁹M)。钙拮抗剂硝苯地平消除了NPY的收缩作用以及NPY诱导的NA收缩增强,但不影响对[³H]NA释放的突触前抑制。受体结合研究表明,股动脉中α₁与α₂肾上腺素能受体的比例为30:1。分别通过哌唑嗪结合和可乐定结合发现,NPY对α₁或α₂肾上腺素能受体结合位点的数量或α₂结合位点的亲和力没有引起任何可检测到的变化。NPY还抑制肠系膜上动脉、基底动脉以及股静脉和门静脉中TNS诱发的[³H]NA释放(42% - 86%)。在酚妥拉明存在的情况下,NPY仍然抑制门静脉中TNS诱发的[³H]NA分泌。NPY使基底动脉明显收缩,增加门静脉中自发收缩的收缩力,而在肠系膜上动脉和股静脉中仅观察到微弱反应。在肠系膜上动脉中,NPY显著增强了NA诱导的收缩,在门静脉中仅略有增强,而在股静脉中无影响。总之,在所有测试的血管中,NPY通过一种硝苯地平抗性作用抑制TNS诱发的[³H]NA分泌。此外,NPY发挥可变的、依赖Ca²⁺的血管收缩作用以及增强NA和TNS收缩。